PharMedica

Company Overview

Snapshot

Founded in March 2008 by Yoram Rubin, PharMedica operates with 11–50 employees. The company has completed one funding round and in February 2024, secured a grant from the Israel Innovation Authority.

Business overview

PharMedica is a biopharmaceutical company specializing in the development of a polymeric-based delivery platform for controlled and sustained release of drugs, nutraceuticals, and food additives. Its core technology utilizes a unique and proprietary polymeric matrix to deliver active substances directly to targeted body parts via an intraoral transmembrane delivery system, enhancing bioavailability and therapeutic effectiveness. The company operates within the Health Tech & Life Sciences sector, specifically focusing on Pharma & Medical Biotechnology and Drug Delivery, serving global markets with products like iCling for dry mouth relief.

Strategic signal

In February 2024, PharMedica secured a grant from the Israel Innovation Authority. This non-equity funding validates the innovative potential of PharMedica's drug delivery platform, signaling strong governmental support for its polymeric-based technology and its applications in improving drug efficacy and patient outcomes.

Company Intelligence Q&A

What is PharMedica's primary focus?

PharMedica develops a polymeric-based delivery platform for controlled and sustained release of drugs, nutraceuticals, and food additives, primarily through orally dissolved films.

When was PharMedica founded?

PharMedica was founded in March 2008.

Who is a co-founder of PharMedica?

Yoram Rubin is a co-founder and CEO of PharMedica.

What significant funding event occurred for PharMedica in early 2024?

In February 2024, PharMedica secured a grant from the Israel Innovation Authority.

What is a key product developed by PharMedica?

PharMedica has developed products such as iCling for dry mouth relief, utilizing its innovative drug delivery technology.